Risk of infections and hospitalisations in inflammatory bowel disease and other immune-mediated diseases on thiopurine therapy: a population-based study

This abstract has open access
Abstract Summary
Abstract ID :
Submission Type
Presentation Upload :
If the file does not load, click here to open/download the file.
Authors (including presenting author) :
Mak WY (1), Tang, Whitney (2), Lam, TO (1), Chan, Francis KL (2), Sung, Joseph JY (2), Ng, Siew C (2)
Affiliation :
(1) Department of Medicine and Therapeutics, Prince of Wales Hospital (2) Department of Medicine and Therapeutics, The Chinese University of Hong Kong
Introduction :
Thiopurines is widely used as an immunosuppressive agent but is associated with a risk of leukopenia. Recently, the presence of NUDT15 variant has been associated with thiopurine-induced leukopenia. Real world data on complications and outcomes of patients with thiopurine-induced leukopenia are scarce.
Objectives :
We aimed to study risks of infections, rates of hospitalisation and intensive care unit (ICU) admission in patients with thiopurine-induced leukopenia.
Methodology :
Patient demographics, disease diagnosis, types of infection, number of hospitalisations and ICU admissions were collected from a territory-wide computerised database of patient records managed by the Hong Kong Hospital Authority covering over 7 million population. Leukopenia was defined as white cell count < 4 x 109/L during thiopurine therapy. The odds ratios for hospitalisation and ICU admissions within 30 days of development of leukopenia were calculated.
Result & Outcome :
From 1 January 2014 to 31 December 2017, 6,185 ethnically Chinese patients received thiopurine (azathioprine or 6-mercaptopurine) for immune-related diseases [32.5% rheumatological diseases, 20.8% inflammatory bowel disease (IBD), 13.3% organ transplantation]. Mean age was 51 years (+/- 19.6 years), and median follow-up was 36 months (interquartile range: 15-47 months). 2,256 patients (36.6%) developed leukopenia during 13,299 person-years of follow-up. Significantly more IBD patients developed thiopurine-induced leukopenia compared with non-IBD patients (45.0% vs. 34.6%, p< 0.01). Patients with thiopurine-induced leukopenia had higher risk of Clostridium difficile infections ( OR 4.95), gastrointestinal (GI) tract infections (OR 2.60), tuberculosis: (OR 2.20), septicaemia (OR: 1.87), fungal infections (OR: 1.75), urinary tract infection (UTI) (OR: 1.63) and pneumonia (OR: 1.30) compared with those without leukopenia. They also had significantly higher number of hospitalizations (mean number, 7.66 vs. 4.17; p< 0.01) and ICU admissions (5.25% vs. 3.25%; p< 0.01). Amongst all patients with thiopurine-induced-leukopenia, IBD patients had more pneumonia, UTI and septicemia than non-IBD patients, but no difference in the number of hospitalizations (mean number, 4.82 vs. 5.60; p=0.10). Conclusion: In a population-based study, 45% of IBD patients developed thiopurine-induced leukopenia and these subjects had a higher risk of infections than non-IBD patients . Thiopurine-induced leukopenia is also associated with more hospitalisations and ICU admissions. Our findings highlight the importance of checking NUDT15 polymorphisms before starting thiopurine therapy.

Similar Abstracts by Type

Abstract ID
Abstract Title
Abstract Topic
Submission Type
Primary Author
Clinical Safety and Quality Service I
HA Staff
Maria SINN Dr
Enhancing Partnership with Patients and Community
HA Staff
Donna TSE
Enhancing Partnership with Patients and Community
HA Staff
Clinical Safety and Quality Service II
HA Staff